Graybug Vision, Inc. (NASDAQ: GRAY) is a clinical-stage biopharmaceutical company that is striving to create novel treatment solutions for diseases that combat vision—threatening diseases and save sight delivering a much better quality of life for patients. The Company is developing therapies for treatment of chronic...
Scholar Rock Holding (NASDAQ: SRRK), a clinical-stage biopharmaceutical Company, announced the grant of a Fast-Track Designation for apitegromab, a selective inhibitor of myostatin activation, intended for the treatment of Spinal Muscular Atrophy (SMA) by the U.S. Food and Drug Administration (FDA). The candidate has previously...
A premier developer and publisher of digital games, SciPlay Corporation (NASDAQ: SCPL) offers free-to-play casino, casual and bingo games to millions of users across the world. The Company is using advanced analytics and data-driven approaches to create authentic, highly thrilling gaming experiences for its users. SciPlay,...
Biotech Companies continue to show resurgence even in these challenging times, with more and more companies persevering with bringing their clinical candidates to fruition. While Vaccine development and therapeutics to combat the COVID-19 pandemic are at the forefront of development activities in the biotech sector,...
A clinical-stage company Minerva Neurosciences, Inc. (NASDAQ: NERV) is developing an array of products for treating Central Nervous System (CNS) disorders, this biopharmaceutical company aims to deliver innovative solutions by harnessing the potential of serotonin receptors to combat disorders such as Schizophrenia and Parkinson’s disease. The...
Heron Therapeutics, Inc. (NASDAQ: HRTX) has a major upcoming catalyst in the form of the upcoming Prescription Drug User Fee Act (PDUFA) date for FDA approval on May 12, 2021 for HDX-011 (Zynrelef). HTX-011 is an extended-release, dual-acting local anesthetic that uses a combination of...
Heska Corporation (NASDAQ: HSKA) is a premier veterinary diagnostic and specialty products manufacturer with presence in major markets such as the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The Company aims to bring leading-edge healthcare solutions to pets, through innovation...
The Company is developing a pipeline of candidates focused on small molecules and biologics that can treat central nervous system (CNS) and immunology disorders. Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) lead candidate for CNS is TNX-102 SL (sublingual formulation of cyclobenzaprine), a non-opioid, centrally-acting analgesic...
